rtmark
LearnBonds.com

Boeing Co. (NYSE:BA) Looking Good as Profits Rise

Boeing Co. NYSE:BA

Boeing Co. (BA) , right before the market opened on Wednesday, October 21, showed off its earnings numbers for the three months through September. Earnings for the quarter came in at $2.52 per share. The firm showed sales totaling $25.80B for the three months.

In the run up to the release of today’s results, analysts following the firm were looking for earnings per share of $2.22 per share from Boeing Co. for the quarter. Sales for the period were forecast to come in at $24.74B by consensus.

Boeing Co. NYSE:BA

Boeing Co. results by comparison

The same three months of 2014 saw Boeing Co. earn $2.52 per share on sales that came to $25.85B. In the last twelve months shares in the firm have gained 11.58% of their value. In the three months leading into the release of these results the firm lost 4.61% 0f their value.

Boeing Company, , together with its subsidiaries, is an aerospace company. The Company operates through five segments: Commercial Airplanes, Boeing Military Aircraft (BMA), Network & Space Systems (N&SS), Global Services & Support (GS&S) and Boeing Capital (BCC). The Defense, Space & Security (BDS) business includes BMA, N&SS and GS&S. The Commercial Airplanes segment develops, produces and markets commercial jet aircraft and provides related support services. The BMA segment is engaged in the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike. The N&SS segment is engaged in the research, development, production and modification of the products and related services.

Analysts look at Boeing Co.

Boeing Co. is expected to make a profit of $0.62 per share for the twelve months of its current fiscal year. Full sales for the year are forecast to come in at B22.81$.

In the last full fiscal year Boeing Co. made $0.92 per share. Sales came in at $23.91B.

Of the 19 analysts covering the firm for Wall Street, 8 analysts said that clients should Buy shares in the firm, 3 analysts rated the shares at Overweight, while 7 analysts said that holding the shares was the best option going forward.

None of the analysts said that clients should keep the shares Underweight in their portfolios, while 1 analyst said that their best idea was to Sell the shares ahead of the release of this earnings report.

Trusted & Regulated Stock & CFD Brokers

Rating

What we like

  • 0% Fees on Stocks
  • 5000+ Stocks, ETFs and other Markets
  • Accepts Paypal Deposits

Min Deposit

$200

Charge per Trade

Zero Commission

Rating

64 traders signed up today

Visit Now

75% of investors lose money when trading CFDs.

Available Assets

  • Total Number of Stocks & Shares5000+
  • US Stocks
  • German Stocks
  • UK Stocks
  • European
  • ETF Stocks
  • IPO
  • Funds
  • Bonds
  • Options
  • Futures
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 Zero Commission
  • NASDAQ Zero Commission
  • DAX Zero Commission
  • Facebook Zero Commission
  • Alphabet Zero Commission
  • Tesla Zero Commission
  • Apple Zero Commission
  • Microsoft Zero Commission

Deposit Method

  • Wire Transfer
  • Credit Cards
  • Bank Account
  • Paypall
  • Skrill
  • Neteller

Rating

What we like

  • Sign up today and get $5 free
  • Fractals Available
  • Paypal Available

Min Deposit

$0

Charge per Trade

$1 to $9 PCM

Rating

Visit Now

Investing in financial markets carries risk, you have the potential to lose your total investment.

Available Assets

  • Total Number of Shares999
  • US Stocks
  • German Stocks
  • UK Stocks
  • European Stocks
  • EFTs
  • IPOs
  • Funds
  • Bonds
  • Options
  • Futures
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 $1 - $9 per month
  • NASDAQ $1 - $9 per month
  • DAX $1 - $9 per month
  • Facebook $1 - $9 per month
  • Alphabet $1 - $9 per month
  • Telsa $1 - $9 per month
  • Apple $1 - $9 per month
  • Microsoft $1 - $9 per month

Deposit Method

  • Wire Transfer
  • Credit Cards
  • Bank Account
Users should remember that all trading carries risks and users should only invest in regulated firms. Views expressed are those of the writers only. Past performance is no guarantee of future results. The opinions expressed in this Site do not constitute investment advice and independent financial advice should be sought where appropriate. This website is free for you to use but we may receive commission from the companies we feature on this site.
Avatar

Victor Alagbe is a seasoned business and finance writer with a specialty in writing about how to invest for the long-term in healthcare, pharmacology, energy and tech stocks. His long-term focus is on stocks that provide a nice mix of growth and income. For the short term, he passionately writes about trading stock options for the excitement and leverage that stock options offer.